Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
30 Abril 2024 - 3:05PM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that
Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is
scheduled to participate in a fireside chat at the BofA Securities
Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT /
7:20 p.m. ET.
A live webcast of the fireside chat will be made available under
Events & Presentations in the Investors section of the Vir
website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on
powering the immune system to transform lives by treating and
preventing infectious diseases and other serious conditions,
including viral-associated diseases. Vir has assembled two
technology platforms that are designed to modulate the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430254007/en/
Media Carly Scaduto Senior Director, Media Relations
cscaduto@vir.bio +1 314-368-5189
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio +1 978-973-9986
Vir Biotechnology (NASDAQ:VIR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Vir Biotechnology (NASDAQ:VIR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024